

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau



WIPO | PCT



(10) International Publication Number

WO 2013/138600 A1

(43) International Publication Date

19 September 2013 (19.09.2013)

(51) International Patent Classification:

C07D 407/06 (2006.01) *A61K 31/341* (2006.01)

C07D 307/36 (2006.01) *A61K 31/403* (2006.01)

C07D 209/82 (2006.01) *A61P 35/00* (2006.01)

C07D 209/30 (2006.01)

(21) International Application Number:

PCT/US2013/031385

(22) International Filing Date:

14 March 2013 (14.03.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/611,932 16 March 2012 (16.03.2012) US

61/624,687 16 April 2012 (16.04.2012) US

(72) Inventors; and

(71) Applicants : **ROSEN, Eliot, M.** [US/US]; 4427 Forest Hill Dr., Fairfax, VA 22030 (US). **BROWN, Milton** [US/US]; 21212 Denit Estates Rd., Brookeville, MD 20833 (US). **FAN, Saijun** [CN/US]; 8010 Thornley Ct., Bethesda, MD 20817 (US). **WALLS, Thomas** [US/US]; 733 Fieldstone Drive, Apt. 304, Leesburg, VA 20176 (US). **SHEIKH, Kathryn** [US/US]; 6986 Gillis Way, Gainesville, VA 20155 (US).

(74) Agents: **DAVIS, Kimberlynn, B.** et al.; Kilpatrick Townsend & Stockton LLP, 1100 Peachtree Street, Suite 2800, Atlanta, GA 30309 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: RADIOPROTECTOR COMPOUNDS

(57) Abstract: Radioprotector compounds including 3,3'-diindolylmethane (DIM) analogs, are provided. Further provided are methods for their use in reducing or preventing radiation damage, killing a tumor cell and protecting a non-tumor cell, and treating cancer.



WO 2013/138600 A1

Radioprotector Compounds

CROSS-REFERENCE TO PRIORITY APPLICATIONS

This application claims priority to U.S. Provisional Application Nos. 61/611,932, filed March 16, 2012, and 61/624,687, filed April 16, 2012, which are incorporated herein by reference in their entireties.

5

STATEMENT REGARDING FEDERALLY FUNDED RESEARCH

This invention was made with government support under grant number R01-CA104546 awarded by the National Institutes of Health. The government has certain rights in the invention.


10

BACKGROUND

Radioprotector agents are used in diagnostic and therapeutic settings to protect normal (e.g., non-cancerous) tissues or structures from radiation damage. These agents are also used as a means of protection in the setting of radiation exposure to the normal population. However, current commercially available radioprotectors are generally too toxic or are insufficiently active to be clinically useful. Furthermore, it is often necessary to administer these agents prior to radiation exposure, which limits the use of these agents to intentional or expected exposures.

SUMMARY


Provided herein are radioprotector compounds. Also provided herein are methods for their use in reducing or preventing radiation damage in a subject, killing a tumor cell and protecting a non-tumor cell, and treating cancer in a subject. A class of compounds described herein includes compounds of the following structure:




and pharmaceutically acceptable salts or prodrugs thereof. In these compounds, L is -CH₂- or -C=O-; and R¹ and R² are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted

25

heteroaryl, or substituted or unsubstituted carbonyl, wherein R^1 and R^2 can optionally combine to form a heterocycle or heteroaryl. Exemplary compounds according to this structure include:



A class of compounds described herein includes compounds of the following structure:





5

and pharmaceutically acceptable salts or prodrugs thereof. In these compounds, R^1 and R^4 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbonyl, or substituted or unsubstituted sulfonyl; R^2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted carbonyl, or substituted or unsubstituted sulfonyl; and R^3 and R^5 are each independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, trifluoromethyl, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted carbonyl, or substituted or unsubstituted carboxyl. In some examples, if R^1 is methyl, R^2 is H, R^3 is H, and R^5 is methyl, then R^4 is not dansyl.


20

Exemplary compounds according to this structure include:







A class of compounds described herein includes compounds of the following structure:




and pharmaceutically acceptable salts or prodrugs thereof. In these compounds, =====

- 5 is a single or double bond; n is 1, 2, or 3; R^1 , R^2 , R^3 , and R^4 are each independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, trifluoromethyl, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted carbonyl, or substituted or
- 10 unsubstituted carboxyl; R^5 is hydrogen or substituted or unsubstituted sulfonyl; R^6 is hydrogen, hydroxyl, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloheteroalkyl, substituted or unsubstituted cycloalkenyl,
- 15 substituted or unsubstituted cycloheteroalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted cycloheteroalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbonyl, substituted or unsubstituted carboxyl, substituted or unsubstituted sulfonyl, or substituted or unsubstituted phosphinic acid; and each R^7 is hydrogen or substituted or unsubstituted alkyl. Exemplary compounds according
- 20 to this structure include:





A class of compounds described herein includes compounds of the following structure:



and pharmaceutically acceptable salts and prodrugs thereof. In these compounds, R^1 is substituted or unsubstituted aryl; and R^2 , R^3 , and R^4 are each independently selected from hydrogen, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.

Also provided herein are compositions comprising one or more compounds described above and a pharmaceutically acceptable carrier.

Further provided herein are methods of reducing or preventing radiation damage in a subject. A method of reducing or preventing radiation damage in a subject includes administering to the subject an effective amount of a compound or composition as described herein. Optionally, the method can further include administering a second therapeutic agent,

such as a radioprotector compound or 3,3'-diindolylmethane (DIM) to the subject. A method of reducing radiation damage in a subject includes administering to the subject an effective amount of 3,3'-diindolylmethane (DIM) or analog thereof after exposure of the subject to radiation. Optionally, the DIM or analog thereof is administered to the subject at least 24
5 hours after exposure of the subject to radiation. A method of reducing or preventing radiation damage in a subject includes administering to the subject an effective amount of 3,3'-diindolylmethane (DIM) or analog thereof, wherein the DIM or analog thereof is microencapsulated. Optionally, the DIM or analog thereof is administered in multiple doses.

Also provided herein are methods of killing a tumor cell and protecting a non-tumor
10 cell. A method of killing a tumor cell and protecting a non-tumor cell includes irradiating the tumor cell with an effective amount of ionizing radiation and administering to the non-tumor cell an effective amount of 3,3'-diindolylmethane (DIM), an effective amount of a compound or composition described herein, or a combination thereof. The irradiating step can be performed prior to the administering step. Optionally, the administering step can be
15 performed prior to the irradiating step. Optionally, the method is performed *in vivo*. Optionally, the method is performed *in vitro*. The tumor cell can be a BRCA₁-deficient tumor cell.

Methods of treating cancer in a subject are also described herein. A method of treating cancer in a subject includes administering to the subject an effective amount of
20 ionizing radiation and administering to the subject an effective amount of 3,3'-diindolylmethane (DIM), an effective amount of a compound or composition described herein, or a combination thereof. Optionally, the cancer is breast cancer (e.g., BRCA₁-deficient breast cancer) or ovarian cancer (e.g., BRCA₁-deficient ovarian cancer).

The details of one or more embodiments are set forth in the drawings and the
25 description below. Other features, objects, and advantages will be apparent from the description and drawings, and from the claims.

DESCRIPTION OF DRAWINGS

Fig. 1 is a graph demonstrating the percentage of survival for rats that were exposed to total body irradiation and were treated with DIM.

30 Fig. 2 contains graphs demonstrating the percentage of survival for rats that were exposed to different doses of total body irradiation (RT), with and without DIM treatment. Panel A shows the results for rats exposed to 13-Gy of γ -rays and then given once daily doses

of DIM (as indicated) for 14-days, with the first administration 10-min after RT. Panels B and C show the results for rats exposed to different doses of RT and then given once daily doses of DIM (75 mg/kg) for 14-days, with the first administration 10-min after RT. Panel D shows the results for rats given a 13-Gy dose of RT and having DIM (75 mg/kg) administered starting at different times post total body irradiation, as indicated. DIM was administered by intraperitoneal (ip) injection with physiological saline as the vehicle and control animals were irradiated but received injections of saline only. Survival was plotted by Kaplan Meier method.

Figs. 3A, 3B, and 3C show that DIM protects against different doses of total body radiation when administered starting 24-hr after irradiation.

Fig. 4 contains data showing that DIM does not protect MDA-MB-231 tumor xenografts grown in athymic nude mice against fractionated radiation. Panel A shows the tumor sizes in mice after mice were administered the indicated treatment (control = no treatment; DIM; RT = total body irradiation; and DIM + RT). Panel B contains Western blots of athymic nude mice containing MDA-MB-231 xenograft tumors grown in the mammary fat pads treated without (-) or with (+) a single dose of DIM (75 mg/kg) at different times before or after irradiation and then received 20-Gy of γ -rays. Panel C contains Western blots for the mice treated or not treated with DIM (75 mg/kg) at the indicated time before or after total body irradiation (TBI, 20-Gy). S1988 in rat ATM corresponds to S1981 in human ATM.

Fig. 5 contains Western blots showing that DIM activates ATM *in vivo*. Figure 5A shows Sprague-Dawley rats treated without (-) or with (+) DIM (75 mg/kg) 24-hr before sham-treatment (-) or TBI (+). Figure 5B shows rats treated without (-) or with (+) DIM (75 mg/kg) 1-hr before sham-treatment (-) or TBI (+). Figure 5C shows rats sham-treated (-) or treated with TBI (20-Gy) (+) and administered vehicle (-) or DIM (+) at 10-min after radiation. Phospho-ATM (serine-1988) in rat corresponds to phospho-ATM (serine-1981) in humans.

Fig. 6 contains graphs demonstrating the radioprotection of cultured human cells by DIM. Panels A and B show the surviving fraction of subconfluent proliferating cultures of 184A1 (Panel A) and Hs578Bst (Panel B) cells pre-treated with DIM (0.3 μ M) or vehicle (DMSO) for 24-hr and irradiated using different doses of γ -rays. Panels C and D show the concentration dependence of DIM radioprotection on clonogenic survival of 184A1 (Panel C)

and Hs578Bst (Panel D) cells using a single dose of radiation (8-Gy) and different concentrations of DIM.

Fig. 7 shows that DIM rapidly causes ATM activation and subsequent phosphorylation of down-stream substrates in cultured cells. Figure 7A contains Western blots of subconfluent proliferating 184A1 human mammary epithelial cells exposed to DIM (0.3 μ M) for different time intervals. Phosphorylated or total levels of ATM and of several different ATM substrate proteins were determined, as indicated. As a negative control, cells were treated with a selective inhibitor of ATM kinase activity (KU55933). Figure 7B contains Western blots of 184A1 cells either untreated or treated with radiation (2-Gy of γ -radiation) and/or DIM (0.3 μ M).

Fig. 8 contains a Western blot of subconfluent proliferating 184A1 human mammary epithelial cells exposed to DIM (0.3 μ M) for different time intervals. Phosphorylated or total levels of ATM and of different DNA damage-response proteins were determined, as indicated.

Fig. 9 shows that ATM and BRCA1 are required for radioprotection by DIM. Panel A depicts the clonogenic survival of 184A1 human mammary epithelial cells pre-treated with control-siRNA or ATM-siRNA (50 nM for 48-hr), treated \pm DIM (0.3 μ M) for 24-hr, and irradiated. The extent of knockdown of ATM is shown in the inset Western blot. Panels B and C show the clonogenic survival of ATM-competent (+/+) MRC5 human fibroblasts (Panel B) or ATM mutant (-/-) AT5 human fibroblasts (Panel C) pre-treated \pm DIM (1 μ M) for 24-hr and irradiated. The Western blot inset in Panel C shows the ATM protein levels in MRC5 and AT5 fibroblasts. Panel D shows BRCA1-competent (Brca1+/+) or BRCA1-deficient (Brca1-/-), but otherwise isogenic, mouse embryo fibroblasts pre-treated \pm DIM (0.3 μ M) for 24-hr and then assayed for clonogenic survival in response to radiation.

Fig. 10 shows that DIM protects wild-type but not Mre11 mutant human dermal fibroblasts. Panels A, B, and C show subconfluent proliferating wild-type (CWAT) (Panel A) or Mre11 mutant (ATLD2 (Panel B) and ATLD3 (Panel C)) human skin fibroblasts treated with DIM (0.3 μ M) or vehicle (DMSO) for 24-hr; irradiated with different doses of ^{137}Cs γ -rays; and harvested for clonogenic survival assays. Cell survival values are means \pm SEMs of three replicate dishes. Panel D shows Western blots of wild-type or Mre-11 mutant (ATLD2) fibroblasts treated with DIM (0.3 μ M) or vehicle for 30 min and then subjected to

Western blotting to detect phospho-ATM (S1981), total ATM, phospho-BRCA1 (S1387), total BRCA1, or actin (loading control).

Fig. 11 shows that DIM stimulates DNA repair and inhibits apoptosis. Figures 11A and 11B show subconfluent proliferating 184A1 (Figure 11A) or Hs578Bst (Figure 11B) cells pre-treated \pm DIM (0.3 μ M x 24 hr); exposed to radiation (3-Gy) on ice; and subjected to neutral comet assays at different times post-irradiation. Values of % tail DNA are means \pm ranges of two determinations. Figure 11C shows plasmid strand-rejoining assays carried out using 75 μ g of nuclear lysates from 184A1 cells that were treated with DIM (0.3 μ M) or vehicle (DMSO) for 24-hr with and without ATM kinase inhibitor KU55933 (10 μ M). Panel D shows the apoptosis assays of 184A1 cells pre-treated \pm DIM (0.3 μ M) for 24-hr and irradiated with 6-Gy of γ -rays. At 24-hr after irradiation, cells were analyzed by flow cytometry for apoptosis, by measuring membrane redistribution of phosphatidylserine. The percentage of early and late apoptotic cells for non-irradiated control cells were: vehicle treated, 1.25% and 1.34%, and DIM-treated, 0.54% and 1.02%, respectively.

Fig. 12 contains graphs depicting the clonogenic survival curves of non-tumorigenic human mammary epithelial cell lines Hs5788st after different doses of gamma ray irradiation, with and without KED-4-69 treatment (top left panel), KED-4-46 treatment (top right panel), KED-4-123 treatment (bottom left panel), and THW-5-85 treatment (bottom right panel).


Fig. 13 contains graphs depicting the clonogenic survival curves of non-tumorigenic human mammary epithelial cell lines Hs5788st after a single dose of gamma ray irradiation, with and without DIM treatment (panel A; top left panel), THW-5-85 treatment (panel B; top right panel), KED-4-155 treatment (panel C; bottom left panel), and KED-4-157 treatment (panel D; bottom right panel).

DETAILED DESCRIPTION

Described herein are compounds for use as radioprotectors. Also provided herein are methods for their use. Such methods include reducing or preventing radiation damage in a subject, killing a tumor cell and protecting a non-tumor cell, and treating cancer in a subject. The methods of reducing or preventing radiation damage in a subject, killing a tumor cell and protecting a non-tumor cell, and treating cancer in a subject described herein include administering to the subject one or more radioprotector compounds.

I. Compounds

A class of radioprotector compounds useful in the methods described herein includes compounds represented by **Formula I**:




I

or a pharmaceutically acceptable salt or prodrug thereof.


In **Formula I**, L is $-\text{CH}_2-$ or $-\text{C}=\text{O}-$.

Also, in **Formula I**, R^1 and R^2 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted carbonyl. Optionally, R^1 and R^2 can optionally combine to form a heterocycle or heteroaryl.

Examples of **Formula I** include the following compounds:




Compound I-1 (KED-2-67)



Compound I-2 (KED-2-271)

A class of radioprotector compounds useful in the methods described herein includes compounds represented by **Formula II**:



II

or a pharmaceutically acceptable salt or prodrug thereof.


In **Formula II**, R^1 and R^4 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbonyl, or substituted or unsubstituted sulfonyl. Optionally, R^1 is methyl. Optionally, R^4 is dansyl or benzyl.

Also, in **Formula II**, R^2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted carbonyl, or substituted or unsubstituted sulfonyl. Optionally, R^2 is hydrogen.


Additionally, in **Formula II**, R^3 and R^5 are each independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, trifluoromethyl, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted carbonyl, or substituted or unsubstituted carboxyl. Optionally, R^3 is methyl and R^5 is hydrogen. Optionally, R^3 is hydrogen and R^5 is methyl.

In some examples of **Formula II**, if R^1 is methyl, R^2 is H, R^3 is H, and R^5 is methyl, then R^4 is not dansyl.


Examples of **Formula II** include the following compounds:




Compound II-1 (KED-4-67)



Compound II-2 (KED-4-69)




Compound II-3 (KED-3-63-2)



Compound II-4 (KED-3-63-1)

In some examples, the compound of **Formula II** is not **Compound II-2**.

A class of radioprotector compounds useful in the methods described herein includes compounds represented by **Formula III**:



III

or a pharmaceutically acceptable salt or prodrug thereof.

5 In **Formula III**, ----- is a single or double bond.


Also, in **Formula III**, n is 1, 2, or 3. Optionally, n is 1.

Additionally, in **Formula III**, R¹, R², R³, and R⁴ are each independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, trifluoromethyl, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted amino, substituted or
 10 unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted carbonyl, or substituted or unsubstituted carboxyl. Optionally, R¹, R², R³, and R⁴ are each hydrogen. Optionally, R¹, R², R³, or R⁴ can be pegylated (e.g., -OPEG).

Further, in **Formula III**, R⁵ is hydrogen or substituted or unsubstituted sulfonyl.





15 Optionally, R⁵ is hydrogen, tosyl, or dansyl.

Additionally, in **Formula III**, R⁶ is hydrogen, hydroxyl, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted cycloalkyl, substituted or
 20 unsubstituted cycloheteroalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloheteroalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted cycloheteroalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbonyl, substituted or unsubstituted carboxyl, substituted or unsubstituted sulfonyl, or substituted or unsubstituted phosphinic acid. Optionally, R⁶ is selected from:







Further, in **Formula III**, each R⁷ is hydrogen or substituted or unsubstituted alkyl.


Examples of **Formula III** include the following compounds:

**Compound III-1 (K-4-15)****Compound III-2 (K-4-123)****Compound III-3 (K-4-153)****Compound III-4 (K-4-155)**


5

**Compound III-5 (K-4-157)****Compound III-6 (K-4-159)****Compound III-7 (K-4-23)****Compound III-8 (K-4-49)**


10



Compound III-9 (KED-3-299)




Compound III-10 (KED-4-27)



Compound III-11 (THW-5-85)

5

In some examples, **Formula III** can be represented by **Formula III-A**:




III-A

10


or a pharmaceutically acceptable salt or prodrug thereof.

In **Formula III-A**, R^6 is selected from hydrogen or one of the following structures:



15


In some examples, **Formula III** can be represented by **Formula III-B**:




III-B

or a pharmaceutically acceptable salt or prodrug thereof.

In **Formula III-B**, R^6 is selected from hydrogen or one of the following structures:




In some examples, **Formula III** can be represented by **Formula III-C**:



III-C

In **Formula III-C**, R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , and R^9 are each independently selected from hydrogen, fluoro, chloro, methoxy, phenyl, trifluoromethyl, and dimethylamino.


In some examples, **Formula III** can be represented by **Formula III-D**:



III-D

In **Formula III-D**, R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , and R^{11} are each independently selected from hydrogen, fluoro, chloro, methoxy, phenyl, trifluoromethyl, and dimethylamino. Optionally, R^8 is dimethylamino.

A class of radioprotector compounds useful in the methods described herein includes compounds represented by **Formula IV**:




IV

or a pharmaceutically acceptable salt or prodrug thereof.

In **Formula IV**, R^1 is substituted or unsubstituted aryl.

Also, in **Formula IV**, R^2 , R^3 , and R^4 are each independently selected from hydrogen and substituted or unsubstituted aryl or heteroaryl.

A compound useful in the methods described herein includes 3,3'-diindolylmethane (DIM) as shown below:



3,3'-diindolylmethane (DIM)

In some examples, the DIM is microencapsulated.

As used herein, the terms alkyl, alkenyl, and alkynyl include straight- and branched-chain monovalent substituents. Examples include methyl, ethyl, isobutyl, 3-butenyl, and the like. Ranges of these groups useful with the compounds and methods described herein include C_1 - C_{20} alkyl, C_2 - C_{20} alkenyl, and C_2 - C_{20} alkynyl. Additional ranges of these groups useful with the compounds and methods described herein include C_1 - C_{12} alkyl, C_2 - C_{12} alkenyl, C_2 - C_{12} alkynyl, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_4 alkyl, C_2 - C_4 alkenyl, and C_2 - C_4 alkynyl.

Heteroalkyl, heteroalkenyl, and heteroalkynyl are defined similarly as alkyl, alkenyl, and alkynyl, but can contain O, S, or N heteroatoms or combinations thereof within the backbone. Ranges of these groups useful with the compounds and methods described herein include C_1 - C_{20} heteroalkyl, C_2 - C_{20} heteroalkenyl, and C_2 - C_{20} heteroalkynyl. Additional ranges of these groups useful with the compounds and methods described herein include C_1 - C_{12} heteroalkyl, C_2 - C_{12} heteroalkenyl, C_2 - C_{12} heteroalkynyl, C_1 - C_6 heteroalkyl, C_2 - C_6

heteroalkenyl, C₂-C₆ heteroalkynyl, C₁-C₄ heteroalkyl, C₂-C₄ heteroalkenyl, and C₂-C₄ heteroalkynyl.

The terms cycloalkyl, cycloalkenyl, and cycloalkynyl include cyclic alkyl groups having a single cyclic ring or multiple condensed rings. Examples include cyclohexyl, cyclopentylethyl, and adamantanyl. Ranges of these groups useful with the compounds and methods described herein include C₃-C₂₀ cycloalkyl, C₃-C₂₀ cycloalkenyl, and C₃-C₂₀ cycloalkynyl. Additional ranges of these groups useful with the compounds and methods described herein include C₅-C₁₂ cycloalkyl, C₅-C₁₂ cycloalkenyl, C₅-C₁₂ cycloalkynyl, C₅-C₆ cycloalkyl, C₅-C₆ cycloalkenyl, and C₅-C₆ cycloalkynyl.

The terms heterocycloalkyl, heterocycloalkenyl, and heterocycloalkynyl are defined similarly as cycloalkyl, cycloalkenyl, and cycloalkynyl, but can contain O, S, or N heteroatoms or combinations thereof within the cyclic backbone. Ranges of these groups useful with the compounds and methods described herein include C₃-C₂₀ heterocycloalkyl, C₃-C₂₀ heterocycloalkenyl, and C₃-C₂₀ heterocycloalkynyl. Additional ranges of these groups useful with the compounds and methods described herein include C₅-C₁₂ heterocycloalkyl, C₅-C₁₂ heterocycloalkenyl, C₅-C₁₂ heterocycloalkynyl, C₅-C₆ heterocycloalkyl, C₅-C₆ heterocycloalkenyl, and C₅-C₆ heterocycloalkynyl.

Aryl molecules include, for example, cyclic hydrocarbons that incorporate one or more planar sets of, typically, six carbon atoms that are connected by delocalized electrons numbering the same as if they consisted of alternating single and double covalent bonds. An example of an aryl molecule is benzene. Heteroaryl molecules include substitutions along their main cyclic chain of atoms such as O, N, or S. When heteroatoms are introduced, a set of five atoms, e.g., four carbon and a heteroatom, can create an aromatic system. Examples of heteroaryl molecules include furan, pyrrole, thiophene, imadazole, oxazole, pyridine, and pyrazine. Aryl and heteroaryl molecules can also include additional fused rings, for example, benzofuran, indole, benzothiophene, naphthalene, anthracene, and quinoline. The aryl and heteroaryl molecules can be attached at any position on the ring, unless otherwise noted.

The alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocycloalkyl, heterocycloalkenyl, or heterocycloalkynyl molecules used herein can be substituted or unsubstituted. As used herein, the term substituted includes the addition of an alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocycloalkyl, heterocycloalkenyl, or heterocycloalkynyl group to a position attached to

the main chain of the alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocycloalkyl, heterocycloalkenyl, or heterocycloalkynyl, e.g., the replacement of a hydrogen by one of these molecules. Examples of substitution groups include, but are not limited to, hydroxyl, halogen (e.g., F, Br, Cl, or I), and carboxyl groups. Conversely, as used herein, the term unsubstituted indicates the alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocycloalkyl, heterocycloalkenyl, or heterocycloalkynyl has a full complement of hydrogens, i.e., commensurate with its saturation level, with no substitutions, e.g., linear decane ($-(CH_2)_9-CH_3$).

II. Pharmaceutical Formulations

The compounds described herein or derivatives thereof can be provided in a pharmaceutical composition. Depending on the intended mode of administration, the pharmaceutical composition can be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, or suspensions, preferably in unit dosage form suitable for single administration of a precise dosage. The compositions will include a therapeutically effective amount of the compound described herein or derivatives thereof in combination with a pharmaceutically acceptable carrier and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, or diluents. By pharmaceutically acceptable is meant a material that is not biologically or otherwise undesirable, which can be administered to an individual along with the selected compound without causing unacceptable biological effects or interacting in a deleterious manner with the other components of the pharmaceutical composition in which it is contained.

As used herein, the term carrier encompasses any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, lipid, stabilizer, or other material well known in the art for use in pharmaceutical formulations. The choice of a carrier for use in a composition will depend upon the intended route of administration for the composition. The preparation of pharmaceutically acceptable carriers and formulations containing these materials is described in, e.g., Remington's Pharmaceutical Sciences, 21st Edition, ed. University of the Sciences in Philadelphia, Lippincott, Williams & Wilkins, Philadelphia Pa., 2005. Examples of physiologically acceptable carriers include buffers, such as phosphate buffers, citrate buffer, and buffers with other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers, such as polyvinylpyrrolidone; amino acids such

as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrans; chelating agents, such as EDTA; sugar alcohols, such as mannitol or sorbitol; salt-forming counterions, such as sodium; and/or nonionic surfactants, such as TWEEN[®] (ICI, Inc.; Bridgewater, New Jersey),
5 polyethylene glycol (PEG), and PLURONICS[™] (BASF; Florham Park, NJ).

Compositions containing the compound described herein or derivatives thereof suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous
10 and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of
15 surfactants.

These compositions may also contain adjuvants, such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be promoted by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. Isotonic agents, for example, sugars, sodium
20 chloride, and the like may also be included. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

Solid dosage forms for oral administration of the compounds described herein or derivatives thereof include capsules, tablets, pills, powders, and granules. In such solid
25 dosage forms, the compounds described herein or derivatives thereof is admixed with at least one inert customary excipient (or carrier), such as sodium citrate or dicalcium phosphate, or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders, as for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, (c) humectants, as for example, glycerol, (d)
30 disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate, (e) solution retarders, as for example, paraffin, (f) absorption accelerators, as for example, quaternary ammonium compounds, (g) wetting agents, as for example, cetyl alcohol, and glycerol monostearate, (h)

adsorbents, as for example, kaolin and bentonite, and (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents.

5 Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethyleneglycols, and the like.

 Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and others known in the art. They
10 may contain opacifying agents and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedding compositions that can be used are polymeric substances and waxes. The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.

15 Liquid dosage forms for oral administration of the compounds described herein or derivatives thereof include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl
20 acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, and fatty acid esters of sorbitan, or mixtures of these substances, and the like.

 Besides such inert diluents, the composition can also include additional agents, such
25 as wetting, emulsifying, suspending, sweetening, flavoring, or perfuming agents.

 Suspensions, in addition to the active compounds, may contain additional agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.

30 Compositions of the compounds described herein or derivatives thereof for rectal administrations are optionally suppositories, which can be prepared by mixing the compounds with suitable non-irritating excipients or carriers, such as cocoa butter, polyethyleneglycol or a suppository wax, which are solid at ordinary temperatures but liquid

at body temperature and, therefore, melt in the rectum or vaginal cavity and release the active component.

Dosage forms for topical administration of the compounds described herein or derivatives thereof include ointments, powders, sprays, and inhalants. The compounds described herein or derivatives thereof are admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants as may be required. Ophthalmic formulations, ointments, powders, and solutions are also contemplated as being within the scope of the compositions.

The compositions can include one or more of the compounds described herein and a pharmaceutically acceptable carrier. As used herein, the term pharmaceutically acceptable salt refers to those salts of the compound described herein or derivatives thereof that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of subjects without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds described herein. The term salts refers to the relatively non-toxic, inorganic and organic acid addition salts of the compounds described herein. These salts can be prepared *in situ* during the isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate mesylate, glucoheptonate, lactobionate, methane sulphonate, and laurylsulphonate salts, and the like. These may include cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. (See S.M. Barge et al., *J. Pharm. Sci.* (1977) 66, 1, which is incorporated herein by reference in its entirety, at least, for compositions taught therein.)

Administration of the compounds and compositions described herein or pharmaceutically acceptable salts thereof can be carried out using therapeutically effective amounts of the compounds and compositions described herein or pharmaceutically acceptable salts thereof as described herein for periods of time effective to treat a disorder. The effective

amount of the compounds and compositions described herein or pharmaceutically acceptable salts thereof as described herein may be determined by one of ordinary skill in the art and includes exemplary dosage amounts for a mammal of from about 0.5 to about 200mg/kg of body weight of active compound per day, which may be administered in a single dose or in the form of individual divided doses, such as from 1 to 4 times per day. Alternatively, the dosage amount can be from about 0.5 to about 150mg/kg of body weight of active compound per day, about 0.5 to 100mg/kg of body weight of active compound per day, about 0.5 to about 75mg/kg of body weight of active compound per day, about 0.5 to about 50mg/kg of body weight of active compound per day, about 0.5 to about 25mg/kg of body weight of active compound per day, about 1 to about 20mg/kg of body weight of active compound per day, about 1 to about 10mg/kg of body weight of active compound per day, about 20mg/kg of body weight of active compound per day, about 10mg/kg of body weight of active compound per day, or about 5mg/kg of body weight of active compound per day. Those of skill in the art will understand that the specific dose level and frequency of dosage for any particular subject may be varied and will depend upon a variety of factors, including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the species, age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate of excretion, drug combination, and severity of the particular condition.

III. Methods of Making the Compounds

The compounds described herein can be prepared in a variety of ways known to one skilled in the art of organic synthesis or variations thereon as appreciated by those skilled in the art. The compounds described herein can be prepared from readily available starting materials. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by one skilled in the art.


Variations on **Formula I**, **Formula II**, **Formula III**, and **Formula IV** include the addition, subtraction, or movement of the various constituents as described for each compound. Similarly, when one or more chiral centers are present in a molecule, the chirality of the molecule can be changed. Additionally, compound synthesis can involve the protection and deprotection of various chemical groups. The use of protection and deprotection, and the selection of appropriate protecting groups can be determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in Wuts and

Greene, Protective Groups in Organic Synthesis, 4th Ed., Wiley & Sons, 2006, which is incorporated herein by reference in its entirety.


Reactions to produce the compounds described herein can be carried out in solvents, which can be selected by one of skill in the art of organic synthesis. Solvents can be substantially nonreactive with the starting materials (reactants), the intermediates, or products under the conditions at which the reactions are carried out, i.e., temperature and pressure. Reactions can be carried out in one solvent or a mixture of more than one solvent. Product or intermediate formation can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., ^1H or ^{13}C) infrared spectroscopy, spectrophotometry (e.g., UV-visible), or mass spectrometry, or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography.

The compounds described by **Formula I** can be made, for example, using reactions shown in **Schemes 1** and **2**:

Scheme 1: Synthesis of Compound I-1




Scheme 2: Synthesis of Compound I-2



As shown above in **Schemes 1** and **2**, the synthesis of **Compound I-1** and **Compound I-2** began with the deprotonation of furan with t-butyl lithium followed by addition into an aryl aldehyde. The resulting alcohol was then oxidized to a ketone using manganese dioxide. For **Compound I-2**, the carbonyl was reduced using lithium aluminum hydride (LAH).

The compounds described by **Formula II** can be made, for example, using reactions shown in **Scheme 3**:


Scheme 3:




As shown above in **Scheme 3**, **Compounds II-1, II-2, II-3, and II-4** were synthesized by benzyl protecting 4-iodophenol, coupling the resulting product with 4-bromo-3-nitroanisole, and then cyclizing the coupled product using triphenylphosphine to provide **Compounds II-4 and II-3**. The compounds were deprotected using palladium on carbon and then dansylated in the presence of triethylamine in dichloromethane to provide **Compounds II-2 and II-1**.

The compounds described by **Formula III** can be made, for example, using reactions shown in **Schemes 4-7**:


Scheme 4:




Scheme 5:



Scheme 6:



Scheme 7:



As shown above in **Schemes 4 and 5**, **Compounds III-3, III-4, III-5, and III-6** were synthesized from commercially available racemic or (S)-indoline-2-carboxylic acid. Specifically, the hydrogen on the indoline nitrogen was substituted for a tosyl or dansyl group in the presence of triethylamine (TEA) in dichloromethane (DCM). **Compounds III-7 and III-9** were also synthesized from (S)-indoline-2-carboxylic acid by substituting the hydrogen on the indoline nitrogen for either a tosyl or dansyl group, and then converting the carboxylic acid to the Weinreb amide after activating with carbonyl diimidazole (CDI). **Compounds III-8 and III-10** were prepared from **Compounds III-7 and III-9**, respectively, by adding methyl lithium (MeLi) in tetrahydrofuran (THF). Following similar procedures, indole-2-carboxylic acid was used to synthesize **Compound III-1**, which was then treated with methyl lithium in THF to form **Compound III-2**.

IV. Methods of Use

Provided herein are methods to reduce or prevent radiation damage in a subject. The methods include administering to a subject an effective amount of one or more of the compounds or compositions described herein, or a pharmaceutically acceptable salt or prodrug thereof. The expression "effective amount," when used to describe an amount of compound in a method, refers to the amount of a compound that achieves the desired pharmacological effect or other effect, for example, an amount that results in a reduction to radiation damage to tissue. The compounds and compositions described herein or pharmaceutically acceptable salts thereof are useful for reducing or preventing radiation damage in humans, including, without limitation, pediatric and geriatric populations, and in animals, e.g., veterinary applications.

Further described herein is a method for treating cancer in a subject. The method includes administering to the subject an effective amount of ionizing radiation and then administering to the subject an effective amount of a compound or composition as described herein (e.g., a compound according to one or more of **Formula I**, **Formula II**, **Formula III**, **Formula IV**, DIM, or microencapsulated DIM). Optionally, the compound according to one or more of **Formula I**, **Formula II**, **Formula III**, or **Formula IV** is microencapsulated. Optionally, the cancer is breast cancer, such as BRCA₁-deficient breast cancer. Optionally, the cancer is ovarian cancer, such as BRCA₁-deficient breast cancer. Optionally, the compound or composition can be administered to the subject before or after the subject has been exposed to radiation. For example, the compound or composition can be administered to the subject 1 minute or more, 2 minutes or more, 5 minutes or more, 10 minutes or more, 15 minutes or more, 30 minutes or more, 45 minutes or more, 1 hour or more, 2 hours or more, 3 hours or more, 4 hours or more, 5 hours or more, 10 hours or more, 15 hours or more, 20 hours or more, or 24 hours or more after exposure. Optionally, the compound or composition can be administered in multiple doses.

The methods of reducing or preventing radiation and treating cancer in a subject can further comprise administering to the subject a therapeutic agent. Thus, the provided compositions and methods can include one or more additional agents. The one or more additional agents and the compounds described herein or pharmaceutically acceptable salts or prodrugs thereof can be administered in any order, including concomitant, simultaneous, or sequential administration. Sequential administration can be temporally spaced order of up to several days apart. The methods can also include more than a single administration of the one or more additional agents and/or the compounds described herein or pharmaceutically acceptable salts or prodrugs thereof. The administration of the one or more additional agents and the compounds described herein or pharmaceutically acceptable salts or prodrugs thereof can be by the same or different routes and concurrently or sequentially.

Therapeutic agents include, but are not limited to, chemotherapeutic agents and radioprotector compounds. The therapeutic agent can, for example, be a chemotherapeutic agent. A chemotherapeutic agent is a compound or composition effective in inhibiting or arresting the growth of an abnormally growing cell. Thus, such an agent may be used therapeutically to treat cancer as well as other diseases marked by abnormal cell growth. Illustrative examples of chemotherapeutic compounds include, but are not limited to, Amifostine.

Any of the aforementioned therapeutic agents can be used in any combination with the compositions described herein. Combinations are administered either concomitantly (e.g., as an admixture), separately but simultaneously (e.g., via separate intravenous lines into the same subject), or sequentially (e.g., one of the compounds or agents is given first followed by the second). Thus, the term combination is used to refer to concomitant, simultaneous, or sequential administration of two or more agents.

The methods and compounds as described herein are useful for both prophylactic and therapeutic treatment. For prophylactic use, a therapeutically effective amount of the compounds and compositions or pharmaceutically acceptable salts thereof as described herein are administered to a subject prior to onset (e.g., before obvious signs of cancer or before radiation exposure), during early onset (e.g., upon initial signs and symptoms of cancer or radiation exposure), or after the development of cancer or exposure to radiation. Prophylactic administration can occur for several days to years prior to the manifestation of symptoms of cancer or prior to radiation exposure. Therapeutic treatment involves administering to a subject a therapeutically effective amount of the compounds and compositions or pharmaceutically acceptable salts thereof as described herein after cancer is diagnosed or radiation exposure is identified.

The methods and compounds described herein are also useful in killing a tumor cell and protecting a non-tumor cell. The methods include irradiating the tumor cell with an effective amount of ionizing radiation and administering to the non-tumor cell an effective amount of a compound or composition as described herein. Optionally, the tumor cell is a BRCA₁-deficient tumor cell. The irradiating step can be performed prior to the administering step or the administering step can be performed prior to the irradiating step. Optionally, the method is performed *in vivo*. Optionally, the method is performed *in vitro*.

The methods herein for prophylactic and therapeutic treatment optionally comprise selecting a subject with or at risk of being exposed to radiation (e.g., military personnel or the civil population under a heightened security due to terrorist threats).

V. Kits

Also provided herein are kits for reducing or preventing radiation damage in a subject or for treating cancer in a subject. A kit can include any of the compounds or compositions described herein. For example, a kit can include 3,3'-diindolylmethane (e.g., microencapsulated DIM), a compound of **Formula I**, **Formula II**, **Formula III**, **Formula IV**, or combinations thereof. Optionally, the compound according to one or more of

Formula I, Formula II, Formula III, and Formula IV is microencapsulated. A kit can further include one or more additional agents, such as anti-cancer agents (e.g., Amifostine). A kit can include an oral or intraperitoneal formulation of any of the compounds or compositions described herein. A kit can additionally include directions for use of the kit (e.g., instructions for treating a subject), a container, a means for administering the compounds or compositions (e.g., a syringe), and/or a carrier.

As used herein the terms treatment, treat, or treating refer to a method of reducing one or more symptoms of a disease or condition. Thus, in the disclosed method, treatment can refer to a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the severity of one or more symptoms of the disease or condition. For example, a method for treating a disease is considered to be a treatment if there is a 10% reduction in one or more symptoms or signs (e.g., size of the tumor or rate of tumor growth) of the disease in a subject as compared to a control. As used herein, control refers to the untreated condition (e.g., the tumor cells not treated with the compounds and compositions described herein). Thus the reduction can be a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any percent reduction in between 10% and 100% as compared to native or control levels. It is understood that treatment does not necessarily refer to a cure or complete ablation of the disease, condition, or symptoms of the disease or condition.

As used herein, the terms prevent, preventing, and prevention of a disease or disorder refer to an action, for example, administration of a composition or therapeutic agent, that occurs before or at about the same time a subject begins to show one or more symptoms of the disease or disorder, which inhibits or delays onset or severity of one or more symptoms of the disease or disorder.

As used herein, references to decreasing, reducing, or inhibiting include a change of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or greater as compared to a control (e.g., untreated) level. Such terms can include, but do not necessarily include, complete elimination.

As used herein, subject means both mammals and non-mammals. Mammals include, for example, humans; non-human primates, e.g., apes and monkeys; cattle; horses; sheep; rats; mice; pigs; and goats. Non-mammals include, for example, fish and birds.

Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application.

The examples below are intended to further illustrate certain aspects of the methods and compositions described herein, and are not intended to limit the scope of the claims.

EXAMPLES

Example 1: DIM as a Radioprotector - Cultured Cells Studies

5 DIM, a metabolite of indole-3-carbinol and a proposed cancer agent, is a potent radiation protector in cultured cells and in rodents (mice and rats). The preparation of DIM that was used for most experiments was a microencapsulated form of DIM produced by BioResponse Nutrients (Boulder, CO). This microencapsulated form of DIM is designed with specific excipients (e.g., alpha-tocopherol succinate and phosphatidylcholine) to provide enhanced absorption and, therefore, enhanced bioavailability. In cultured cells, both enhanced absorption DIM and crystalline DIM work very well as radioprotectors, but in animals, the enhanced absorption DIM is a better radioprotector than crystalline DIM, probably, in part, due to greater bioavailability. In various types of cultured (e.g., fibroblasts and epithelial cells), DIM strongly protects against ionizing radiation (Cs-60 gamma radiation or high energy X-rays), based on rigorously performed clonogenic survival assays.

15 Not to be bound by theory, a mechanism of action is that DIM, in the absence of any DNA damage, appears to hyper-activate the cellular DNA damage-response machinery [including signaling from the "MRN complex" (a trio of proteins involved in DNA damage sensing) to ATM (ataxia-telangiectasia mutated) to BRCA1, CHK1, p53 and other DNA damage response and repair factors]. This leads to enhanced cellular capacity to repair DNA damage. DIM also stimulates the activity of DNA-dependent protein kinase (DNA-PK), another protein involved in the repair of double-strand DNA breaks. Although these are probably not the only mechanisms by which DIM works, they appear to be involved in the radioprotection by DIM. These mechanisms are unique for a radioprotector, because most existing compounds that are radioprotectors do not work by modifying the biological response of cells to radiation, as does DIM. DIM-mediated radioprotection is observed at high doses of radiation as well as low doses (less than 200 cGy); thus DIM works throughout a wide spectrum of radiation doses. Fold-protection of different doses of DIM are in the range of 20 to 100-fold or higher. Data showing DIM radiation protection of cultured cells are provided in the attached grant proposals.

Example 2: DIM as a Radioprotector

The activity for DIM as a radioprotector and a mitigator of radiation damage, via stimulation of an ATM signaling cascade, is demonstrated herein. DIM causes activation of ATM signaling without itself causing DNA damage.

5 **Materials and Methods**

Cells lines and culture

BRCA1-deficient mouse embryonic fibroblasts (MEFs) and wild-type MEFs were obtained. 184A1 and Hs578Bst cells were cultured. MCF-7 and T47D cells were grown in DMEM plus 5% fetal calf serum, l-glutamine (5 mM), non-essential amino acids (5 mM),
10 penicillin (100 U/ml), and streptomycin (100 µg/ml) (all obtained from BioWhittaker, Walkersville, MD).

Reagents

A bioavailable formulation of 3,3'-diindolylmethane (BR-DIM) was obtained from Bioresponse (Boulder, CO). BR-DIM is a microencapsulated preparation that has increased
15 oral bioavailability than unformulated crystalline DIM. It is herein referred to as "DIM".

Radiation survival curves

Following the indicated treatment(s), subconfluent proliferating cells were irradiated with different doses of ^{137}Cs γ -rays, harvested using trypsin, and plated at different densities in the absence or presence of DIM (as indicated) for colony formation (clonogenic survival)
20 assays, as described in Zhang et al., Radiat Res, 161:667-674 (2004). Values of surviving fraction are means \pm SEMs of triplicate plates.

siRNA treatment

Proliferating cells were treated with gene-specific siRNA or control-siRNA using siRNA Transfection Reagent (Santa Cruz Biotechnology, Santa Cruz, CA). ATM-siRNA
25 (sc-29761), BRCA1-siRNA (sc-29219), and control-siRNA (sc-37007) were purchased from Santa Cruz. The cells were exposed to the indicated siRNA (50 nM) for at least 48 hr; and the efficacy of the knockdown was confirmed by Western blotting.

DNA repair and apoptosis assays

Comet assays. Following the indicated treatment, neutral or alkaline comet assays
30 were performed.

DNA strand rejoining assay. After the indicated cell treatment(s), nuclear lysates were prepared and aliquots of lysate (50 or 75 µg of nuclear protein) were tested for their ability to rejoin a plasmid (pEGFP-1, Clontech) that had been linearized using restriction

enzyme SmaI. The reaction products were detected by Southern blotting, which was performed with a digoxigenin-labeled enhanced green fluorescent protein RNA probe. The percent rejoined plasmids 98984 was determined by densitometric quantification of the bands corresponding to rejoined and unrejoined plasmid.

5 *Western blotting*

Western blotting was performed. The primary antibodies were as follows: rabbit polyclonal anti-BRCA1 (sc-642, Santa Cruz); mouse monoclonal α -actin (sc-1616, Santa Cruz); anti-phospho-BRCA1 (S1387) [AB3257, Millipore (Billerica, MA)]; mouse monoclonal anti-ATM (sc-73615, Santa Cruz,); anti-phospho-ATM (S1981); anti-CHK2 (05-649, mouse monoclonal, Millipore); anti-phospho-CHK2 (T68) (ab32055, rabbit monoclonal, Abcam, Cambridge, MA); anti-p53 (ab2433, rabbit polyclonal, Abcam), and rabbit polyclonal anti-phospho-p53 (S15) (ab38497, Abcam).

Animal experiments

Studies utilized Sprague-Dawley rats (age 12-16 weeks, weight 200 ± 30 g) or C57BL/6 mice (6-8 weeks, *ca.* 20 g). Animals were administered DIM or carrier (physiological saline) by intraperitoneal injection at the doses and schedules indicated, subjected to total body irradiation using ^{60}Co γ -rays (0.96 Gy/min), and followed for survival up to 30 days. Mice that either appeared to be moribund or died were considered not to have survived.

20 *Statistical methods*

For *in vivo* studies, animal survival was plotted using Kaplan-Meier statistics; and the survival curves were compared using the log-rank test. Other statistical comparisons were made using two-tailed t-tests.

Results

25 *In vivo radiation protection and mitigation by DIM*

In rats and mice, DIM very potently protects against very high (supra-lethal) doses of radiation: doses so high (e.g., 13-Gy) that, in the absence of DIM, none of the animals survive past 10-days. Female Sprague-Dawley rats (age 12-16 weeks; weight 200 ± 30 gm) were randomized into two groups of 30 animals each, one of which received 13-Gy ^{60}Co γ -rays (0.96-Gy/min) as a single dose plus 0.1-mL physiological saline intraperitoneally and the other of which received 13-Gy ^{60}Co γ -rays plus DIM (7.5 mg/kg body weight, ip). Both groups received daily ip injections of 0.1-mL starting 1 day before irradiation and ending 10 days after irradiation. Survival was monitored for 30 days, and the results were plotted using

Kaplan-Meier statistics. At a dose of 13-Gy of total body irradiation (TBI), survival of DIM-treated animals is as high as 50-60% at 30 days (see Figure 1). At lower doses of TBI, the survival of DIM-treated animals was corresponding higher. Radioprotection by DIM was dependent upon the dose of DIM utilized, the timing of administration relative to the TBI, and the number of times DIM was administered (see below). In these experiments, DIM was administered by intraperitoneal injection for convenience, but previous studies indicate excellent biodistribution when DIM (BR-DIM) is given orally. DIM can be given to mice by oral gavage at 250 mg/kg with no toxicity and wide tissue distribution.

Figure 2a shows dose-dependent protection of Sprague-Dawley (SD) rats given once daily injections of DIM for 14-days starting 10-min after a 13-Gy dose of TBI. Here, control animals all died before day 10, while the 30-day survival rates were 60%, 50%, 20%, and 0% when the doses of DIM were 75, 45, 15, and 7.5 mg/kg, respectively. When the first DIM dose was given 24 hours prior to TBI (13-Gy), a much lower daily dose of DIM (7.5 mg/kg) yielded high survival (55%) at 30 days ($P < 0.001$, log-rank test). Thus, if one DIM dose can be given before radiation, protection can be achieved with a very low dose of DIM. DIM similarly protected C57BL/6 mice against TBI, indicating that protection is not species-specific.

In another study, different TBI doses were given followed by once daily DIM injections (75 mg/kg for 14-days starting 10-min post TBI). DIM conferred large increases in survival at each radiation dose (Figs. 2b and 2c). From these data, the dose-modifying factor (DMF) for DIM (*ie.*, the ratio of $LD_{50/30}$ values (+) vs (-) DIM) administered shortly after radiation is estimated to be 1.9. Using a single TBI dose of 13-Gy and variable timing for the first injection of DIM, survival at 30-days was 50%, 60%, 40%, and 30%, respectively, when the first DIM dose was given 10-min, 2-hr, 4-hr, or 24-hr post-TBI (Fig. 2d). Thus, delaying DIM treatment for 2-hr caused no falloff in survival. Even when DIM was delayed for 24-hr, survival was still appreciable (30%), suggesting that DIM acts as a radiation mitigator.

Further studies were performed in SD rats, where DIM (75 mg/kg) was given intraperitoneally for 14-days starting 24-hr post-TBI, using 20 rats per group. The survival rates at 30-days were 60%, 40%, and 20% for vehicle-treated animals at 5, 7, and 9-Gy, respectively, and 90%, 70%, and 50% for DIM-treated rats (see Fig. 3). Taken with the 13-Gy data, the DMF for DIM started 24-hr post-TBI was 1.6.

DIM does not alter growth or radiosensitivity of MDA-MB-231 breast cancer xenografts

MDA-MB-231 human breast cancer cells were grown as xenograft tumors in the mammary fat pads of athymic nude mice. Starting on day 8 after tumor cell inoculation, the mice were either sham-treated or irradiated using a regimen of 5-daily treatments of 7-Gy each, for a total dose of 35-Gy. Starting one day before irradiation or sham treatment, the mice were given once daily injections of DIM (75 mg/kg) or vehicle for a total of six injections. DIM had no effect on the growth of non-irradiated or irradiated tumors (Fig. 4a). Similar results were observed in a second experiment using a lower dose of radiation (20-Gy in 5-Gy fractions).

DIM activates ATM in normal tissues

The ability of DIM to activate ATM *in vivo* was examined utilizing an antibody to phospho-ATM (serine-1981), a marker of ATM activation. As shown in Fig. 4b, ATM was constitutively active (phosphorylated) in MDA-MB-231 tumor tissue extracts and was not further activated in response to DIM alone, radiation alone (20-Gy), or DIM plus radiation. No increases in phospho-ATM levels were observed whether DIM was given 24-hr before, 4-hr before, or 10-min after irradiation. In contrast, in normal mouse kidney tissue, basal phospho-ATM levels were low; and phospho-ATM levels were significantly increased by DIM, radiation (20-Gy), and DIM plus radiation. Phospho-ATM levels were determined 24-hr post irradiation and they appeared to be greater following treatment with DIM plus radiation than either agent alone, suggesting that DIM further activates ATM beyond that due to radiation alone.

In additional experiments carried out in rats under different conditions, DIM caused ATM phosphorylation by itself and enhanced the radiation-induced phosphorylation in normal rat kidney, liver, and brain (see Fig. 5). Qualitatively similar results were observed in different tissues whether DIM was administered 24-hr before, 1-hr before, or 10-min after irradiation. In all tissues studied, phospho-ATM levels were elevated at 24-hr after TBI, consistent with the idea that radiation causes ongoing oxidative stress in normal tissues, since most double-strand DNA breaks in irradiated cells are repaired within 2-3 hr. The results suggest that DIM can activate ATM and enhance radiation-induced activation *in vivo*, as a possible mechanism of radioprotection and mitigation.

DIM radioprotection of cultured cells

Significant radioprotection by DIM was observed using MTT assays in which cells were exposed to DIM (0.3 μ M) starting 48-hr before radiation to 5-10 min after irradiation. These assays reflect short-term mechanisms of cell death (*e.g.*, apoptosis) and do not allow

accurate survival determination below 1.5-2 logs. It was next tested whether DIM could protect cultured cells against radiation using clonogenic survival (colony formation) assays. Cells were exposed to DIM (0.3 μ M) for 24-hr, irradiated, and harvested for colony formation assays. Figs. 6a and 6b show the ability of DIM to protect two non-tumorigenic human mammary epithelial cell lines 184A1 and Hs578Bst. Figs. 6c and 6d show the effect of DIM concentration on protection, using a single radiation dose (8-Gy). These studies revealed concentration-dependent protection up to 0.3 μ M of DIM and additional studies showed further increases in cell survival at higher DIM concentrations up to 3.0 μ M, where the protective effect leveled off. Time course studies also revealed that DIM significantly protected cells even when it was administered starting shortly after irradiation.

DIM stimulates an ATM signaling pathway in cultured cells

DIM alone (0.3 μ M) caused rapid activation of ATM, indicated by phosphorylation on serine-1981 in 184A1 cells (Fig. 7a) and other cell types. Subsequent to ATM, phosphorylation was observed on two ATM substrates (BRCA1 and CHK2) at the ATM sites on these proteins (Fig. 7a). These phosphorylations were blocked by a selective ATM kinase inhibitor (KU55933, 10 μ M), suggesting that DIM stimulates an ATM signaling pathway. In a study combining ionizing radiation and DIM (0.3 μ M), at 30-min after radiation, the combination of DIM and radiation gave greater phosphorylation of ATM and several substrates than either agent alone (Fig. 7b), suggesting that in the setting of DNA damage, DIM might function to “hyper-activate” ATM. In additional studies, increased phosphorylation of ATM and NBS1, an ATM substrate, was observed after only 1-min of exposure to DIM, followed by phosphorylation of p53, and later BRCA1 and CHK2 on their ATM sites (Fig. 8). DIM also stimulated the phosphorylation of CHK1 on serine-345. CHK1 is a DDR protein for which DNA damage-induced phosphorylation is thought to be mediated primarily by ATR rather than ATM. However, some studies have identified an additional role for ATM in the regulation of CHK2 phosphorylation. Taken together, these findings show that DIM, which does cause DNA damage, can stimulate a DNA damage response (DDR)-like response in cultured cells.

ATM, BRCA1, and MRE11 are required for radioprotection

The ability of DIM to protect ATM-deficient cells against radiation was tested. Knock-down of ATM using siRNA caused marked sensitization of 184A1 cells to radiation, as expected, and abolished DIM-induced radioprotection (Fig. 9a). In contrast, cells treated with control-siRNA showed strong radioprotection by DIM. Using a genetic approach, ATM

null ($ATM^{-/-}$) human fibroblasts (AT5 cells, which were derived from an ataxia-telangiectasia patient) were considerably more radiosensitive than control ($ATM^{+/+}$) human fibroblasts (MRC5) and were not protected at all by DIM (Figs. 9b and 9c). Furthermore, $BRCA1^{-/-}$ mouse embryo fibroblasts were also more sensitive to radiation than $BRCA1^{+/+}$ fibroblasts and were not protected by DIM (Fig. 9d). Taken together, these findings suggest that not only does DIM stimulate ATM signaling but also that an ATM/BRCA1 signaling pathway is required for DIM-mediated protection of cultured cells against ionizing radiation.

MRE11 is a component of the “MRN” (MRE11-RAD50-NBS1) complex, which is thought to act as a DNA damage sensor and up-stream activator of ATM. Individuals with MRE11 mutations exhibit an ataxia-telangiectasia-like disorder (ATLD) similar to those with inherited ATM mutations. Whereas wild-type human dermal fibroblasts (CWAT) exhibited protection by DIM (0.3 μ M), MRE11-deficient cell lines (ATLD2 and ATLD3) were more radiosensitive than CWAT and were not protected by DIM (Fig. 10a-c). In contrast to wild-type fibroblasts (CWAT), MRE11-deficient cells (ATLD2) showed no DIM-induced phosphorylation of ATM or BRCA1 after a 30 min exposure to DIM. These findings suggest that in addition to ATM and BRCA1, MRE11 is also required for DIM-mediated radioprotection.

DIM stimulates DNA repair and inhibits apoptosis

Since ATM is known to have a major role in the repair of radiation-induced double-strand breaks (DSBs) of DNA, it was tested whether DIM could stimulate the repair of DSBs. The neutral comet assay is an electrophoretic method to measure DNA damage that reflects DSBs. The percent of tail DNA after irradiation reflects the number of DSBs. Pre-treatment with DIM (0.3 μ M) for 24-hr reduced the % of comet tail DNA (reflecting DSBs) at 30-min and 2-hr post radiation (3-Gy), suggesting more rapid DNA repair (Figs. 11a and 11b). A DNA strand-rejoining assay based on the ability of cell nuclei to rejoin a linearized plasmid (pEGFP-1) was also performed, detected by Southern blotting. This assay reflects the process of non-homologous end joining (NEHJ). In Fig. 11c, nuclear extracts of vehicle-treated cells showed a modest ability to rejoin DNA strands that was greatly enhanced by pre-treatment with DIM. KU55833 blocked DIM-induced strand-rejoining, suggesting it is ATM-dependent. In various cell types, control cells gave 0-2% strand-rejoining and DIM-treated cells showed 40-60% rejoining.

Pre-treatment with DIM for 24-hr blocked radiation-induced apoptosis in 184A1 cells, as determined by flow cytometry of annexin V-labeled cells (Fig. 11d). The anti-apoptotic

effect of DIM could also reflect ATM signaling, since ATM is known to stimulate anti-apoptotic pathways (eg., NF- κ B) in irradiated cells.

Example 3: Radioprotector Compounds

Novel compounds were synthesized, which we have tested for their ability to protect cells against radiation in cultured cells. Some of these compounds gave strong levels of radiation protection similar to, slightly greater than, or slightly less than DIM, including compounds KED-4-157, KED-4-155, KED-4-159, KED-4-153, KED-4-123, KED-4-46, THW-5-85, and KED-4-69. None of these compounds are predicted to be free-radical scavengers or to be genotoxic. For reference, clonogenic radiation survival curves of cultured human mammary epithelial cells treated without or with DIM are shown in Figure 6, panels A and B. In these studies, human mammary epithelial cells at about 70-80% of confluency were treated with DIM (0.3 μ M) or vehicle (DMSA) for 24 hours. The cells were then irradiated using different doses of 137 Cs gamma rays, harvested, plated at different densities in the presence of DIM (0.3 μ M) or vehicle, respectively, incubated for 14 days, and then counted for colony formation. In Figure 6, panels A and B, the clonogenic survival curves are shown using non-tumorigenic human mammary epithelial cell lines Hs5788st (panel B) or 184A1 (panel A). All cell survival values are means \pm SEMs of three replicate dishes.

Radiation dose-response curves for the same cell type treated with different DIM-related analogs are shown in Figure 12. Cells at about 70-80% confluency were treated with vehicle (DMSO) or with the indicated compound (1 μ M) for 24 hours, irradiated using different doses of 137 Cs gamma rays, harvested, plated at different densities in the presence of the compound (0.3 μ M) or vehicle, respectively, incubated for 14 days, and then counted for colony formation. In Figure 12, clonogenic survival curves are shown using non-tumorigenic human mammary epithelial cell line Hs578Bst. All cell survival values are means \pm SEMs of three replicate dishes. Like DIM, these analogs gave strong radiation protection, with fold-increases in survival in the range of (20-100)-fold at different doses of radiation.

A comparison of the survival enhancing effects of DIM against three different compounds is shown in Figure 13. A single dose of radiation (8-Gy) was used and different concentrations of DIM (panel A), THW-5-85 (panel B), KED-4-155 (panel C), or KED-4-157 (panel D). Each analog was at least as potent as DIM at the different concentrations tested. Some analogs gave greater protection at some concentrations. Taken together, these


findings show that new classes of small molecule drug-like compounds related to DIM as the prototype have been discovered that act as potent radiation protectors. DIM and the synthesized compounds protect a variety of different cell types against radiation.

The mechanism of radiation protection is similar to that of DIM, but these compounds could also have other effects that are independent of DIM. A combination of two of these agents (THW-5-85 plus KED-4-157) gave considerably greater radiation protection than did either agent alone and also gave considerably greater radiation protection than did DIM, showing combination therapy may be more beneficial than single agent therapy. These agents are of interest because they have the potential to make superior radioprotectors and mitigators to DIM. Although when used as single agents in cultured cells, the degree of protection is similar to that afforded by DIM, in combination they are superior to DIM. Importantly, when used in animals or humans, DIM is still limited by its bioavailability. Thus, an agent that is significantly more bioavailable than absorption enhanced DIM (BR-DIM) makes a superior radioprotector and/or radiation mitigator in animals and humans even though at the cellular level it is only as good as DIM.

The compounds and methods of the appended claims are not limited in scope by the specific compounds and methods described herein, which are intended as illustrations of a few aspects of the claims and any compounds and methods that are functionally equivalent are within the scope of this disclosure. Various modifications of the compounds and methods in addition to those shown and described herein are intended to fall within the scope of the appended claims. Further, while only certain representative compounds, methods, and aspects of these compounds and methods are specifically described, other compounds and methods and combinations of various features of the compounds and methods are intended to fall within the scope of the appended claims, even if not specifically recited. Thus, a combination of steps, elements, components, or constituents may be explicitly mentioned herein; however, all other combinations of steps, elements, components, and constituents are included, even though not explicitly stated.

WHAT IS CLAIMED IS:

1. A compound of the following structure:




or a pharmaceutically acceptable salt or prodrug thereof, wherein:

L is $-CH_2-$ or $-C(=O)-$; and

R^1 and R^2 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted carbonyl,


wherein R^1 and R^2 can optionally combine to form a heterocycle or heteroaryl.

2. The compound of claim 1, wherein the compound is




or a pharmaceutically acceptable salt or prodrug thereof.

3. The compound of claim 1, wherein the compound is



or a pharmaceutically acceptable salt or prodrug thereof.

4. A compound of the following structure:



or a pharmaceutically acceptable salt or prodrug thereof, wherein


R^1 and R^4 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbonyl, or substituted or unsubstituted sulfonyl;

R^2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted carbonyl, or substituted or unsubstituted sulfonyl; and

R^3 and R^5 are each independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, trifluoromethyl, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted carbonyl, or substituted or unsubstituted carboxyl,


wherein if R^1 is methyl, R^2 is H, R^3 is H, and R^5 is methyl, then R^4 is not dansyl.

5. The compound of claim 4, wherein the compound is




or a pharmaceutically acceptable salt or prodrug thereof.

6. The compound of claim 4, wherein the compound is




or a pharmaceutically acceptable salt or prodrug thereof.

7. The compound of claim 4, wherein the compound is



or a pharmaceutically acceptable salt or prodrug thereof.

8. A compound of the following structure:



or a pharmaceutically acceptable salt or prodrug thereof, wherein:

===== is a single or double bond;

n is 1, 2, or 3;


R¹, R², R³, and R⁴ are each independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, trifluoromethyl, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted carbonyl, or substituted or unsubstituted carboxyl;

R⁵ is hydrogen or substituted or unsubstituted sulfonyl;

R⁶ is hydrogen, hydroxyl, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloheteroalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloheteroalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted cycloheteroalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbonyl, substituted or unsubstituted carboxyl, substituted or unsubstituted sulfonyl, or substituted or unsubstituted phosphinic acid; and


each R⁷ is hydrogen or substituted or unsubstituted alkyl.

9. The compound of claim 8, wherein the compound is




or a pharmaceutically acceptable salt or prodrug thereof.

10. The compound of claim 8, wherein the compound is




or a pharmaceutically acceptable salt or prodrug thereof.

11. The compound of claim 8, wherein the compound is




or a pharmaceutically acceptable salt or prodrug thereof.

12. The compound of claim 8, wherein the compound is




or a pharmaceutically acceptable salt or prodrug thereof.

13. The compound of claim 8, wherein the compound is




or a pharmaceutically acceptable salt or prodrug thereof.

14. The compound of claim 8, wherein the compound is




or a pharmaceutically acceptable salt or prodrug thereof.

15. The compound of claim 8, wherein the compound is




or a pharmaceutically acceptable salt or prodrug thereof.

16. The compound of claim 8, wherein the compound is




or a pharmaceutically acceptable salt or prodrug thereof.

17. The compound of claim 8, wherein the compound is




or a pharmaceutically acceptable salt or prodrug thereof.

18. The compound of claim 8, wherein the compound is




or a pharmaceutically acceptable salt or prodrug thereof.

19. The compound of claim 8, wherein the compound is



or a pharmaceutically acceptable salt or prodrug thereof.

20. A compound of the following structure:



or a pharmaceutically acceptable salt or prodrug thereof, wherein


R^1 is substituted or unsubstituted aryl; and

R^2 , R^3 , and R^4 are each independently selected from hydrogen, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.

21. A composition comprising one or more of the compounds according to any of claims 1-20 and a pharmaceutically acceptable carrier.

22. A method of reducing or preventing radiation damage in a subject, comprising:

administering to the subject an effective amount of a compound or composition according to any of claims 1-21, a compound of the following structure:




or a combination of these.

23. The method of claim 22, further comprising administering a second therapeutic agent to the subject.

24. The method of claim 23, wherein the second therapeutic agent is a radioprotector compound.

25. The method of claim 23, wherein the second therapeutic agent is 3,3'-diindolylmethane (DIM).

26. A method of killing a tumor cell and protecting a non-tumor cell, comprising:
irradiating the tumor cell with an effective amount of ionizing radiation; and
administering to the non-tumor cell an effective amount of 3,3'-diindolylmethane (DIM),
an effective amount of a compound or composition according to any of claims 1-21, a
compound of the following structure:




or a combination of these.

27. The method of claim 26, wherein the irradiating step is performed prior to the administering step.

28. The method of claim 26, wherein the administering step is performed prior to the irradiating step.

29. The method of any of claims 26-28, wherein the method is performed *in vivo*.
30. The method of any of claims 26-28, wherein the method is performed *in vitro*.
31. The method of any of claims 26-30, wherein the tumor cell is a BRCA₁-deficient tumor cell.
32. A method of treating cancer in a subject, comprising:
administering to the subject an effective amount of ionizing radiation; and
administering to the subject an effective amount of 3,3'-diindolylmethane (DIM), an effective amount of a compound or composition according to any of claims 1-21, a compound of the following structure:



or a combination of these.

33. The method of claim 32, wherein the cancer is breast cancer or ovarian cancer.
34. The method of claim 33, wherein the breast cancer is BRCA₁-deficient breast cancer.
35. The method of claim 33, wherein the ovarian cancer is BRCA₁-deficient ovarian cancer.
36. A method of reducing radiation damage in a subject, comprising:
administering to the subject an effective amount of 3,3'-diindolylmethane (DIM) after exposure of the subject to radiation.
37. The method of claim 36, wherein the DIM is administered to the subject at least 24 hours after exposure of the subject to radiation.
38. A method of reducing or preventing radiation damage in a subject, comprising:
administering to the subject an effect amount of 3,3'-diindolylmethane (DIM),
wherein the DIM is microencapsulated.

39. The method of any of claims 36-38, wherein the DIM is administered in multiple doses.




Figure 1




Figure 2

3 / 16




Figure 3A




Figure 3B




Figure 3C




Figure 4

6 / 16




Figure 5A




Figure 5B




Figure 5C




Figure 6




Figure 7A

184A1 (30-min after irradiation)




Figure 7B




Figure 8




Figure 9




Figure 10




Figure 11A




Figure 11B




Figure 11C

14 / 16




Figure 11D




Figure 12




Figure 13

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2013/031385**A. CLASSIFICATION OF SUBJECT MATTER****C07D 407/06(2006.01)i, C07D 307/36(2006.01)i, C07D 209/82(2006.01)i, C07D 209/30(2006.01)i, A61K 31/341(2006.01)i, A61K 31/403(2006.01)i, A61P 35/00(2006.01)i**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D 407/06; C07D 519/00; C07D 209/12; A61K 31/404; C07C 253/30; C07D 473/34; C07D 207/333; C07D 209/00; A61P 35/00; A61K 31/403; C07D 209/14; C07D 307/36; C07D 209/82; C07D 209/30; A61K 31/341

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models

Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
eKOMPASS(KIPO internal)**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 05235068 A (MINAI MASAYOSHI et al.) 10 August 1993 See column 3	1,2,21
A		3
X	WO 2008-051523 A3 (GEORGETOWN UNIVERSITY et al.) 02 May 2008 See claims 32, 33	4,6,7,21
A		5
X	WO 2008-003703 A1 (BIOVITRUM AB (PUBL) et al.) 10 January 2008 See claim 1	8-16,21
A		17-20
X	WO 2011-163195 A1 (INCYTE CORPORATION et al.) 29 December 2011 See page 25	8,17,21
A		9-16,18-20
X	US 3838167 A (CHARLES D. JONES) 24 September 1974 See claim 1	8,14,21
A		9-13,15-20

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

25 June 2013 (25.06.2013)

Date of mailing of the international search report

28 June 2013 (28.06.2013)

Name and mailing address of the ISA/KR

Korean Intellectual Property Office
189 Cheongsa-ro, Seo-gu, Daejeon Metropolitan City,
302-701, Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

NA, Young Min

Telephone No. 82-42-481-8466



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2013/031385

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JAROSZ et al. `Enantiospecific reduction of prochiral ketones of aromatic type to optically active alcohols in <i>Nigrospora oryzae</i> culture`, Journal of Basic Microbiology, 1996, vol. 36, No. 4, pp. 245-253. See Table 1	8, 18, 21
A		9-17, 19, 20
X	WO 2007-040166 A1 (DAINIPPON SUMITOMO PHARMA CO., LTD. et al.) 12 April 2007 See claim 1	8, 19, 21
A		9-18, 20
X	HUGENBERG et al. `Oxidative desulfurization-fluorination of thioethers. Application for the synthesis of fluorinated nitrogen containing building blocks`, Organic & Biomolecular Chemistry, 2010, Vol. 8, pp. 5682-5691. See Scheme 1	20, 21

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/US2013/031385**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 22-39
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 22-39 pertain to methods for treatment of the human body by therapy and thus relate to a subject matter which this International Searching Authority is not required to search under Article 17(2)(a)(i) of the PCT and Rule 39.1(iv) of the Regulations under the PCT.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2013/031385

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 05235068 A	10.08.1993	EP 0339599 A3 EP 0339599 B1 JP 01-279846A JP 08-030014B2	06.03.1991 21.08.1996 10.11.1989 27.03.1996
WO 2008-051523 A3	02.05.2008	US 2010-0130579 A1 WO 2008-051523 A2	27.05.2010 02.05.2008
WO 2008-003703 A1	10.01.2008	AU 2007-271188 A1 AU 2007-271188 B2 BR PI0712898A2 CA 2655694 A1 CN 101484420 A EP 2046741 A1 EP 2046741 B1 ES 2398299 T3 JP 2009-541461 A JP 2009-541461 T NZ 573371 A RU 2009103313 A RU 2449990 C2 US 2008-0032968 A1 US 7812017 B2	10.01.2008 01.11.2012 08.01.2013 10.01.2008 15.07.2009 15.04.2009 31.10.2012 15.03.2013 26.11.2009 26.11.2009 28.01.2011 10.08.2010 10.05.2012 07.02.2008 12.10.2010
WO 2011-163195 A1	29.12.2011	US 2011-312979 A1	22.12.2011
US 3838167 A	24.09.1974	None	
WO 2007-040166 A1	12.04.2007	AU 2006-298164 A1 CA 2623154 A1 CN 101321726 A EP 1930320 A1 KR 10-2008-0063288 A US 2010-0190768 A1	12.04.2007 12.04.2007 10.12.2008 11.06.2008 03.07.2008 29.07.2010